Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Amadeus Fire: Operatives Ergebnis bricht ein (4investors) +++ AMADEUS FIRE Aktie -3,37%

MEDIFAST Aktie

 >MEDIFAST Aktienkurs 
9.45 EUR    +3.9%    (TradegateBSX)
Ask: 9.6 EUR / 358 Stück
Bid: 9.1 EUR / 361 Stück
Tagesumsatz: 1411 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
MEDIFAST Aktie über LYNX handeln
>MEDIFAST Performance
1 Woche: -7,2%
1 Monat: -10,7%
3 Monate: -7,0%
6 Monate: -20,4%
1 Jahr: -42,2%
laufendes Jahr: +0,5%
>MEDIFAST Aktie
Name:  MEDIFAST DL-,001
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US58470H1014 / 889384
Symbol/ Ticker:  MDF (Frankfurt) / MED (NYSE)
Kürzel:  FRA:MDF, ETR:MDF, MDF:GR, NYSE:MED
Index:  -
Webseite:  https://medifastinc.com/
Profil:  Medifast Inc. is a prominent player in the health and wellness industry, focused on providing scientifically developed weight management and healthy living products. With a range of offerings that inc..
>Volltext..
Marktkapitalisierung:  100.05 Mio. EUR
Unternehmenswert:  -37.57 Mio. EUR
Umsatz:  363.16 Mio. EUR
EBITDA:  10.95 Mio. EUR
Nettogewinn:  0.21 Mio. EUR
Gewinn je Aktie:  0.02 EUR
Schulden:  10.36 Mio. EUR
Liquide Mittel:  84.12 Mio. EUR
Operativer Cashflow:  6.08 Mio. EUR
Bargeldquote:  3.71
Umsatzwachstum:  -39.55%
Gewinnwachstum:  -96.79%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Div. Historie:  18.09.23 - 1.4157€
26.06.23 - 1.4157€
>weitere anzeigen...
Insiderhandel:  -
Suchwörter:  MEDIFAST
Letzte Datenerhebung:  18.02.26
>MEDIFAST Kennzahlen
Aktien/ Unternehmen:
Aktien: 10.99 Mio. St.
Frei handelbar: 96.7%
Rückkaufquote: 0.31%
Mitarbeiter: 504
Umsatz/Mitarb.: 1.01 Mio. EUR
Analysten:
Analystenrating: Neutral
Kursziel: 46.79%
Bewertung:
KGV: 507.11
KGV lG: -
KUV: 0.27
KBV: 0.54
PEG-Ratio: -
EV/EBITDA: -
Rentabilität:
Bruttomarge: 72.44%
Gewinnmarge: 0.06%
Operative Marge: -1.33%
Managementeffizenz:
Gesamtkaprendite: 0.09%
Eigenkaprendite: 0.12%
>MEDIFAST Peer Group
Gesundheit
 
18.02.26 - 01:00
Medifast (MED) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
 
Medifast (MED) delivered earnings and revenue surprises of +27.63% and +6.05%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?...
18.02.26 - 00:30
Medifast outlines $270M–$300M 2026 revenue target as CEO transition and metabolic health focus drive execution (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
18.02.26 - 00:00
Medifast (MED) Q4 2025 Earnings Call Transcript (Fool)
 
Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...
17.02.26 - 23:42
Earnings Call: Medifast verfehlt Gewinnprognose für Q4 2025 deutlich (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
17.02.26 - 22:12
Medifast GAAP EPS of -$1.65 misses by $0.83, revenue of $75.1M beats by $3.7M (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
17.02.26 - 22:09
Medifast Announces Fourth Quarter and Full Year 2025 Financial Results (Business Wire)
 
BALTIMORE--(BUSINESS WIRE)--Medifast (NYSE: MED), the health and wellness company known for its science-backed, coach-guided lifestyle system, today reported results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Revenue of $75.1 million, with revenue per active earning coach of $4,664 Independent active earning coaches of 16,100 Net loss of $18.1 million, or $1.65 per diluted share ("EPS"), which includes the tax provision charge to establish a non-cash valuation allowance on the Company's deferred tax balance of $12.1 million (or $1.10 per diluted share) Cash, cash equivalents, and investment Securities of $167.3 million and no debt Full Year 2025 Revenue of $385.8 million Net loss of $18.7 million, or $1.70 per diluted share, which includes the tax provision charge to establish a non-cash valuation allowance on the Company's deferred tax balance of $12.1 million (or $1.10 per diluted share) “As we enter 2026, Medifast is moving from defining its business...
16.02.26 - 22:01
What to Expect from Medifast′s Earnings (Benzinga)
 
Importance Rank:  1 read more...
10.02.26 - 17:30
Analysts Estimate Medifast (MED) to Report a Decline in Earnings: What to Look Out for (Zacks)
 
Medifast (MED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations....
03.02.26 - 22:06
Medifast to Announce Financial Results for the Fourth Quarter and Full Year Ended December 31, 2025 (Business Wire)
 
BALTIMORE--(BUSINESS WIRE)--Medifast (NYSE: MED), the health and wellness company known for its science-backed, coach-guided lifestyle system, will announce financial results for the quarter and full year ended December 31, 2025 on Tuesday, February 17, 2026, after market close. The Company will host a conference call to discuss the results with additional comments and details. Company participants will be Dan Chard, Chairman and Chief Executive Officer, Nick Johnson, President, and Jim Maloney, Chief Financial Officer. The conference call is scheduled to begin at 4:30 p.m. ET on February 17, 2026. The call will be broadcast live over the Internet, hosted on the Investor Relations section of Medifast's website at www.MedifastInc.com or directly at https://viavid.webcasts.com/starthere.jsp?ei=1749244&tp_key=cd37227dbd and will be archived online and available through May 17, 2026. To join via telephone, listeners may dial (201) 389-0879. A telephonic playback will be available from 7:30 p.m. ET, February ...
22.01.26 - 19:45
Medifast′s Q4 Guidance Remains Weak: When Does Growth Return? (Zacks)
 
MED sees weak Q4 guidance after steep revenue declines, but a metabolic health pivot targets stabilization and recovery....
08.01.26 - 20:30
Medifast Shifts to Metabolic Health: A Durable Growth Path? (Zacks)
 
MED is pivoting to metabolic health, using clinical data and new products to address root causes beyond GLP-1 weight loss....
05.01.26 - 15:03
Medifast Announces Planned Leadership Transition (Business Wire)
 
 Nicholas Johnson Appointed President, and Expected to Succeed Dan Chard as CEO in June 2026; Chard to Remain ChairmanBALTIMORE--(BUSINESS WIRE)--Medifast, Inc. (NYSE: MED) today announced a planned leadership transition designed to provide continuity and stability as the company continues its evolution toward metabolic health. Medifast Chairman & Chief Executive Officer Dan Chard has informed the Board of Directors that he plans to step down as Chief Executive Officer in June 2026. Chard will continue to serve as Chairman of the Board following the transition. The Board has appointed Medifast's Chief Field Operations Officer Nicholas Johnson as President of Medifast, effective immediately. Johnson will work closely with Chard and the Board during a deliberate transition period and is expected to assume the role of Chief Executive Officer following Chard's departure. “This decision comes at a moment when I feel confidence in the direction of Medifast, the strength of our leadership team, and the path...
30.12.25 - 20:30
Medifast New Product Line Planned: Can Innovation Reignite Demand? (Zacks)
 
MED plans a new product line rooted in metabolic synchronization science, upgrading its core offerings as it shifts beyond weight loss....
24.12.25 - 20:30
Medifast′s Third-Quarter Revenue Fell 36%: Is Stabilization Near? (Zacks)
 
MED witnesses revenue plunge as its coach base shrank, but restructuring and productivity initiatives aim to stabilize results by late 2025....
18.12.25 - 19:45
Can Medifast Overcome GLP-1 Pressure With Its Growth Strategy? (Zacks)
 
MED targets long-term metabolic health with programs that preserve muscle and support lasting wellness amid GLP-1 adoption....
04.11.25 - 19:00
Medifast′s Q3 Loss Wider Than Expected, Sales Decline 36% Y/Y (Zacks)
 
MED's third-quarter results reflect pressure from fewer active OPTAVIA Coaches, but it is steering toward metabolic health for growth....
04.11.25 - 00:42
Medifast outlines Q4 2025 revenue guidance of $65M–$80M amid strategic shift to metabolic health solutions (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
03.11.25 - 23:42
Medifast-Aktie nach Quartalszahlen unter Druck: Umsatz bricht ein (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
31.10.25 - 22:39
Medifast Q3 2025 Earnings Preview (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
21.10.25 - 16:06
Medifast to Announce Financial Results for the Third Quarter Ended September 30, 2025 (Business Wire)
 
BALTIMORE--(BUSINESS WIRE)--Medifast (NYSE: MED), the 40+ year old health and wellness company known for its science-backed, coach-guided lifestyle system, will announce financial results for the quarter ended September 30, 2025 on Monday, November 3, 2025, after market close. The Company will host a conference call to discuss the results with additional comments and details. Company participants will be Dan Chard, Chairman and Chief Executive Officer, and Jim Maloney, Chief Financial Officer. The conference call is scheduled to begin at 4:30 p.m. ET on November 3, 2025. The call will be broadcast live over the Internet, hosted on the Investor Relations section of Medifast's website at www.MedifastInc.com or directly at https://viavid.webcasts.com/starthere.jsp?ei=1737984&tp_key=fe2490eae4 and will be archived online and available through February 3, 2026. To join via telephone, listeners may dial (201) 389-0879. A telephonic playback will be available from 8:30 p.m. ET, November 3, 2025, through Novembe...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Von allen Gütern ist das beste, ein edles Weib zu haben. - Euripides
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!